WhiteBook2_Part2 - 21

Results
Table 1. European Commission funding for Horizon 2020 digestive disease related projects
Digestive disease
Inflammatory bowel disease
Chronic liver diseases (not including disease sub-categories)
Non-alcoholic fatty liver disease
Chronic hepatitis B
Coeliac disease
Alcohol-related liver disease
Chronic hepatitis C
Pancreatitis
Gallbladder and biliary diseases
Irritable bowel syndrome
Eosinophilic oesophagitis
Gastroesophageal reflux disease
Inguinal, femoral, and abdominal hernia
Appendicitis
Dyspepsia
Gastritis and duodenitis
Paralytic ileus and intestinal obstruction
Peptic ulcer disease
Source: authors' compilation using data extracted from CORDIS database.
Funding per project may be assigned to more than one disease.
European Commission funding
€154,049,175
€86,031,462
€54,231,518
€24,259,518
€22,712,561
€6,305,654
€5,504,323
€5,237,429
€4,236,977
€1,720,851
€50,000
€50,000
€50,000
€0
€0
€0
€0
€0
Figure 15 shows the relationship between European Commission funding for Horizon 2020
digestive and non-digestive disease related projects, and the number of DALYs per disease in
the EU in 2019 (for which data were available). Inflammatory bowel disease research
appeared to be very well funded in relation to burden compared with other diseases. With
over 900,000 fewer DALYs, inflammatory bowel disease received over €147 million in
additional research funding compared to alcohol-related liver disease for example. Funding
for non-alcoholic fatty liver disease research appeared to be well funded in relation to
burden compared with other diseases, and funding for chronic hepatitis B research appeared
to be aligned with disease burden. However, most of the digestive diseases analysed
appeared to be under-funded in relation to burden compared with other diseases. Similar
findings were observed when global DALYs were used instead of EU DALYs, although chronic
hepatitis B research appeared to be under-funded in relation to the global burden associated
with this disease (see Appendix).
As an example, we estimate that if nine digestive diseases (gastritis and duodenitis, inguinal,
femoral, and abdominal hernia, peptic ulcer disease, pancreatitis, paralytic ileus and
intestinal obstruction, chronic hepatitis C, gastroesophageal reflux disease, gallbladder and
biliary diseases, and alcohol-related liver disease) received a proportionate amount of
research funding relative to their disease burden, an additional €283 million would have been
allocated to these diseases in total, including almost €83 million for alcohol-related liver
disease research.
White Book 2: Part 2
18
WhiteBook2_Part2

Table of Contents for the Digital Edition of WhiteBook2_Part2
